Evidence map›Paper›PMID 39071392›Full record

ArticlebioRxiv : the preprint server for biology2024

Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response in mice and humans.

Daniel A Skelly, John P Graham, Mingshan Cheng, Mayuko Furuta, Andrew Walter, Thomas A Stoklasek, Hongyuan Yang, Timothy M Stearns, Olivier Poirion, Ji-Gang Zhang and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Daniel A SkellyThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
John P GrahamThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Mingshan ChengThe Jackson Laboratory, Sacramento, CA, USA.
Mayuko FurutaThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Andrew WalterThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Thomas A StoklasekThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Hongyuan YangThe Jackson Laboratory, Sacramento, CA, USA.
Timothy M StearnsThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Olivier PoirionThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Ji-Gang ZhangThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Jessica D S GrassmannSingle Cell Biology Lab, The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Diane LuoSingle Cell Biology Lab, The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
William F FlynnSingle Cell Biology Lab, The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Elise T CourtoisSingle Cell Biology Lab, The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Chih-Hao ChangThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
David V SerrezeThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Francesca MenghiThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Laura G ReinholdtThe Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, USA.
Edison T LiuThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

Funding

Shared Resource ManagementP30CA034196 · NCI · JACKSON LABORATORY · PI Paul Robson · 1985 to 2026
$61.9M
NCI NIH HHS P30 CA034196
6 · The paper itself

Abstract

Identifying host genetic factors modulating immune checkpoint inhibitor (ICI) efficacy has been experimentally challenging because of variations in both host and tumor genomes, differences in the microbiome, and patient life exposures. Utilizing the Collaborative Cross (CC) multi-parent mouse genetic resource population, we developed an approach that fixes the tumor genomic configuration while varying host genetics. With this approach, we discovered that response to anti-PD-1 (aPD1) immunotherapy was significantly heritable in four distinct murine tumor models (

Identifiers

PMID39071392
PMCPMC11275897

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.